|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CPT2 |
Gene summary for CPT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CPT2 | Gene ID | 1376 |
| Gene name | carnitine palmitoyltransferase 2 | |
| Gene Alias | CPT1 | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | A0A140VK13 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1376 | CPT2 | LZE20T | Human | Esophagus | ESCC | 9.40e-06 | 1.63e-01 | 0.0662 |
| 1376 | CPT2 | LZE24T | Human | Esophagus | ESCC | 9.91e-05 | 1.82e-01 | 0.0596 |
| 1376 | CPT2 | LZE21T | Human | Esophagus | ESCC | 1.66e-02 | 1.58e-01 | 0.0655 |
| 1376 | CPT2 | P1T-E | Human | Esophagus | ESCC | 5.74e-05 | 2.17e-01 | 0.0875 |
| 1376 | CPT2 | P2T-E | Human | Esophagus | ESCC | 5.58e-22 | 3.27e-01 | 0.1177 |
| 1376 | CPT2 | P4T-E | Human | Esophagus | ESCC | 4.37e-11 | 1.79e-01 | 0.1323 |
| 1376 | CPT2 | P8T-E | Human | Esophagus | ESCC | 4.60e-12 | 1.31e-01 | 0.0889 |
| 1376 | CPT2 | P9T-E | Human | Esophagus | ESCC | 3.16e-05 | 9.80e-02 | 0.1131 |
| 1376 | CPT2 | P10T-E | Human | Esophagus | ESCC | 1.97e-12 | 2.16e-01 | 0.116 |
| 1376 | CPT2 | P11T-E | Human | Esophagus | ESCC | 1.58e-06 | 1.69e-01 | 0.1426 |
| 1376 | CPT2 | P12T-E | Human | Esophagus | ESCC | 5.15e-12 | 2.09e-01 | 0.1122 |
| 1376 | CPT2 | P15T-E | Human | Esophagus | ESCC | 9.72e-10 | 1.96e-01 | 0.1149 |
| 1376 | CPT2 | P16T-E | Human | Esophagus | ESCC | 2.04e-16 | 2.10e-01 | 0.1153 |
| 1376 | CPT2 | P17T-E | Human | Esophagus | ESCC | 1.99e-03 | 1.67e-01 | 0.1278 |
| 1376 | CPT2 | P19T-E | Human | Esophagus | ESCC | 1.28e-02 | 3.52e-01 | 0.1662 |
| 1376 | CPT2 | P20T-E | Human | Esophagus | ESCC | 5.18e-12 | 2.44e-01 | 0.1124 |
| 1376 | CPT2 | P21T-E | Human | Esophagus | ESCC | 1.38e-17 | 2.48e-01 | 0.1617 |
| 1376 | CPT2 | P22T-E | Human | Esophagus | ESCC | 2.55e-06 | 1.46e-01 | 0.1236 |
| 1376 | CPT2 | P23T-E | Human | Esophagus | ESCC | 1.69e-10 | 2.93e-01 | 0.108 |
| 1376 | CPT2 | P24T-E | Human | Esophagus | ESCC | 3.14e-07 | 1.32e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:1990542110 | Esophagus | ESCC | mitochondrial transmembrane transport | 72/8552 | 102/18723 | 2.94e-07 | 4.23e-06 | 72 |
| GO:00193958 | Esophagus | ESCC | fatty acid oxidation | 69/8552 | 103/18723 | 9.95e-06 | 9.44e-05 | 69 |
| GO:00344407 | Esophagus | ESCC | lipid oxidation | 71/8552 | 108/18723 | 2.00e-05 | 1.74e-04 | 71 |
| GO:00090628 | Esophagus | ESCC | fatty acid catabolic process | 66/8552 | 100/18723 | 3.21e-05 | 2.66e-04 | 66 |
| GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
| GO:00065757 | Esophagus | ESCC | cellular modified amino acid metabolic process | 112/8552 | 188/18723 | 8.31e-05 | 6.06e-04 | 112 |
| GO:00066358 | Esophagus | ESCC | fatty acid beta-oxidation | 50/8552 | 74/18723 | 1.16e-04 | 8.04e-04 | 50 |
| GO:00723297 | Esophagus | ESCC | monocarboxylic acid catabolic process | 74/8552 | 122/18723 | 6.03e-04 | 3.27e-03 | 74 |
| GO:00442427 | Esophagus | ESCC | cellular lipid catabolic process | 121/8552 | 214/18723 | 8.63e-04 | 4.43e-03 | 121 |
| GO:00442827 | Esophagus | ESCC | small molecule catabolic process | 201/8552 | 376/18723 | 1.35e-03 | 6.41e-03 | 201 |
| GO:00302586 | Esophagus | ESCC | lipid modification | 116/8552 | 212/18723 | 4.90e-03 | 1.89e-02 | 116 |
| GO:01201624 | Esophagus | ESCC | positive regulation of cold-induced thermogenesis | 57/8552 | 97/18723 | 6.43e-03 | 2.35e-02 | 57 |
| GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
| GO:01061066 | Esophagus | ESCC | cold-induced thermogenesis | 80/8552 | 144/18723 | 1.07e-02 | 3.65e-02 | 80 |
| GO:01201616 | Esophagus | ESCC | regulation of cold-induced thermogenesis | 80/8552 | 144/18723 | 1.07e-02 | 3.65e-02 | 80 |
| GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
| GO:00068397 | Liver | Cirrhotic | mitochondrial transport | 112/4634 | 254/18723 | 1.03e-11 | 6.66e-10 | 112 |
| GO:004428211 | Liver | Cirrhotic | small molecule catabolic process | 151/4634 | 376/18723 | 2.20e-11 | 1.34e-09 | 151 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
| hsa04714211 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
| hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
| hsa0541538 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
| hsa04714310 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
| hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
| hsa0471414 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
| hsa0541514 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
| hsa0007121 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
| hsa012122 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
| hsa0332021 | Liver | Cirrhotic | PPAR signaling pathway | 32/2530 | 75/8465 | 1.24e-02 | 3.92e-02 | 2.42e-02 | 32 |
| hsa0471415 | Liver | Cirrhotic | Thermogenesis | 121/2530 | 232/8465 | 5.70e-13 | 1.36e-11 | 8.36e-12 | 121 |
| hsa0541515 | Liver | Cirrhotic | Diabetic cardiomyopathy | 108/2530 | 203/8465 | 1.99e-12 | 4.41e-11 | 2.72e-11 | 108 |
| hsa0007131 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
| hsa012123 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
| hsa0332031 | Liver | Cirrhotic | PPAR signaling pathway | 32/2530 | 75/8465 | 1.24e-02 | 3.92e-02 | 2.42e-02 | 32 |
| hsa0471422 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
| hsa0541522 | Liver | HCC | Diabetic cardiomyopathy | 151/4020 | 203/8465 | 2.72e-15 | 1.01e-13 | 5.63e-14 | 151 |
| hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| hsa0007141 | Liver | HCC | Fatty acid degradation | 33/4020 | 43/8465 | 8.41e-05 | 4.27e-04 | 2.37e-04 | 33 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CPT2 | SNV | Missense_Mutation | c.711N>G | p.Asp237Glu | p.D237E | P23786 | protein_coding | deleterious(0.03) | possibly_damaging(0.631) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
| CPT2 | SNV | Missense_Mutation | rs746186600 | c.1195N>T | p.Pro399Ser | p.P399S | P23786 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| CPT2 | SNV | Missense_Mutation | c.534G>C | p.Leu178Phe | p.L178F | P23786 | protein_coding | deleterious(0) | possibly_damaging(0.53) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CPT2 | SNV | Missense_Mutation | c.623A>G | p.Asn208Ser | p.N208S | P23786 | protein_coding | tolerated(0.07) | benign(0.018) | TCGA-D8-A1JH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | nolvadex | SD | |
| CPT2 | SNV | Missense_Mutation | c.312A>T | p.Lys104Asn | p.K104N | P23786 | protein_coding | tolerated(0.13) | benign(0.154) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CPT2 | SNV | Missense_Mutation | rs750079911 | c.1508G>A | p.Arg503His | p.R503H | P23786 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-D8-A27N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol+adriamycin+cyclophosphamide+herceptin | SD |
| CPT2 | SNV | Missense_Mutation | c.289G>A | p.Glu97Lys | p.E97K | P23786 | protein_coding | tolerated(0.71) | benign(0.012) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| CPT2 | insertion | In_Frame_Ins | novel | c.1556_1557insGATGGG | p.Glu519_Pro520insMetGly | p.E519_P520insMG | P23786 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
| CPT2 | insertion | In_Frame_Ins | novel | c.1558_1559insCTA | p.Pro520_Ser521insThr | p.P520_S521insT | P23786 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
| CPT2 | insertion | Nonsense_Mutation | novel | c.1095_1096insTCACTGATGACAAGGCCAGACACCTCCTGGTCCTAAGGAAAGGAA | p.Ser365_Thr366insSerLeuMetThrArgProAspThrSerTrpSerTerGlyLysGlu | p.S365_T366insSLMTRPDTSWS*GKE | P23786 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1376 | CPT2 | DRUGGABLE GENOME | PERHEXILINE | PERHEXILINE | ||
| 1376 | CPT2 | DRUGGABLE GENOME | PERHEXILINE | PERHEXILINE | ||
| 1376 | CPT2 | DRUGGABLE GENOME | PROPIONYL-L-CARNITINE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |